We also lacked data on key indications and contraindications, such as HbA1c (a key biomarker of diabetes control and indicator for eligibility for SGLT2i and GLP1-RA via the PBS) and further potential factors influencing uptake (e.g. prescriber preferences). This evidence concerns the gene GLP1R and diabetes mellitus.